Public stakeholder meeting: approval, safety monitoring and impact of COVID-19 vaccines in the EU

• Date:
  Friday, 26 March 2021, 13:00 (CET) - 15:15 (CET)
• Location:
  Online
  European Medicines Agency, Amsterdam, the Netherlands
• Twitter:
  Public stakeholder meeting: approval, safety monitoring and impact of COVID-19 vaccines in the EU

Event summary

This third public meeting updated EU citizens about the continued assessment, approval and safety monitoring of COVID-19 vaccines, and their expected impact at community level.

It covered: 

• COVID-19 vaccines approved in the EU and those currently under review;
• post-authorisation activities, including emerging safety data since EU authorisation of the first COVID-19 vaccines;
• ongoing work to address new variants;
• the expected impact of COVID-19 vaccination on our society;
• transparency and the publication of clinical data for COVID-19 vaccines.

The event also allowed the public and stakeholders to further inform EMA of their needs, expectations and any concerns.

Video recordings

Full video recording

 

Update on approved and candidate COVID-19 vaccines in the EU, Marco Cavaleri (EMA)

 

Vaccines safety monitoring – update on emerging data since EU authorisations, Peter Arlett (EMA)

 

Expected impact of COVID-19 vaccination in the European Union, Edoardo Colzani (ECDC)

 

Transparency and publication of clinical data for COVID-19 vaccines, Melanie Carr (EMA)

Documents

Agenda - Public stakeholder meeting: approval, safety monitoring and impact of COVID-19 vaccines in the EU

Presentation - Update on approved and candidate COVID-19 vaccines in the EU (M.Cavaleri, EMA)

Presentation - COVID-19 vaccines safety monitoring (P.Arlett, EMA)

Presentation - Expected impact of COVID-19 vaccination in the European Union (E.Colzani, ECDC)

Presentation - Transparency and publication of clinical data for COVID-19 vaccines (M.Carr, EMA)